Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

View Full Paper
Ask AI
Bookmark
Share

Authors

GMGabriel N. MannisUniversity of California, San FranciscoIAIrina AmitaiTel Aviv UniversityPSPaul J. ShamiUniversity of Utah

Discussion

Loading...

Member takes

Overview

Phase 2 trial reports treatment outcomes in R/R NPM1m AML, suggesting potential for revumenib to improve response rates.

Key Points

  • To evaluate the efficacy and safety of revumenib in patients with R/R NPM1m AML.
  • Phase 2 clinical trial
  • Patients with R/R NPM1m AML received revumenib
  • Primary endpoints included rate of complete remission and safety
  • Secondary endpoints evaluated overall response rate and duration of response
  • Descriptive analysis of duration of response by prior treatment was conducted.
  • 77 patients met efficacy-evaluable criteria, median age 63 years
  • Overall CR+CRh rate was 26.0% with a median duration of CR/CRh of 4.7 months
  • CR+CRh rates varied by prior treatment: 19.3% with venetoclax, 12.9% with FLT3i, 40.0% with IDH1i, and 60.0% with IDH2i
  • 78.6% of patients experienced treatment-related adverse events, with treatment discontinuation in 4.8%.

Cite This Study

Mannis et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da73https://doi.org/10.1182/blood-2025-3418
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study2025 · 5 citations
  2. 2Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability2025 · 2 citations
  3. 3A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed <i>NPM1</i> -mutated acute myeloid leukemia (REVEAL-ND NPM1).2026 · 1 citations
  4. 4A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed <i>NPM1</i> -mutated or <i>KMT2A</i> -rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).2026 · 1 citations
  5. 5Revumenib as maintenance for AML following allogeneic stem cell transplantation.2026